Compare Gilead Sciences, Inc. (GILD) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Walmart Stores Inc — how do they compare? Gilead Sciences, Inc. trades at $133.69 (market cap $163.51B), while Walmart Stores Inc trades at $114.16 (market cap $895.52B). The key difference: Walmart Stores Inc is far larger — about 5.5× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | WMT | |
|---|---|---|
Market Cap | $163.51B | $895.52B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $134.20 |
52-Week Low | $108.22 | $95.05 |
Enterprise Value | $178.05B | $958.97B |
Dividend Yield | 2.49% | 0.88% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Walmart (WMT) trades at $113.70, down 0.94% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.74. Revenue grew to $681.0B in 2025, and net income margin improved to 2.85%. Recent news highlights Walmart's AI initiatives and philanthropic efforts, while technical indicators point to near-term resistance at $115.
The outlook for WMT is positive based on robust fundamentals and analyst consensus, with a price target of $142.10 implying 25% upside. Risks include competitive pressure from Amazon and potential legal issues from recent lawsuits. Institutional sentiment remains bullish, supporting long-term growth prospects amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
